Form 8-K - Current report:
SEC Accession No. 0001558370-25-004606
Filing Date
2025-04-08
Accepted
2025-04-08 17:00:21
Documents
14
Period of Report
2025-04-08
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K otlk-20250408x8k.htm   iXBRL 8-K 30896
  Complete submission text file 0001558370-25-004606.txt   158527

Data Files

Seq Description Document Type Size
2 EX-101.SCH otlk-20250408.xsd EX-101.SCH 4127
3 EX-101.DEF otlk-20250408_def.xml EX-101.DEF 2856
4 EX-101.LAB otlk-20250408_lab.xml EX-101.LAB 17254
5 EX-101.PRE otlk-20250408_pre.xml EX-101.PRE 11370
16 EXTRACTED XBRL INSTANCE DOCUMENT otlk-20250408x8k_htm.xml XML 4786
Mailing Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830
Business Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

EIN.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-37759 | Film No.: 25822680
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)